The indication of ofatumumab is to include clinically isolated syndrome (CIS), relapsing-remitting MS, and active secondary progressive MS in adults. In the ASCLEPIOS trials, ofatumumab demonstrated superior efficacy versus teriflunomide and a favourable safety profile in relapsing-remitting MS patients [2]. Long-term safety data continues to be collected from the open-label phase 3b ALITHIOS extension study.
The overall safety data of all participants in ALITHIOS was reported [1]. This data included 1,230 patients who were randomised to ofatumumab in the core phase 2 APLIOS (12 weeks) or phase 3 ASCLEPIOS I/II (up to 30 months) trials and continued in ALITHIOS, or completed/discontinued the core study and continued the safety follow-up; and 643 patients who were randomised to teriflunomide in ASCLEPIOS I/II and switched to ofatumumab in ALITHIOS.
The overall exposure was 2,118 patient-years.
The most frequently reported adverse events (AEs) were injection-related reactions and upper respiratory tract infections. Most AEs were mild to moderate in severity; the incidence of AEs, serious AEs, or grade 3/4 AEs did not increase in either group. There were no deaths. The overall safety profile was consistent with reports from the core ASCLEPIOS I/II trials. In the newly switched group, injection-related reactions were mild to moderate; none were serious or led to treatment discontinuation. Concerning AEs of special interest: there were no opportunistic infections, hepatitis B reactivation, or progressive multifocal leukoencephalopathy (PML) events. There were no new cases of malignancies in the continuous or newly switched patients either.
- Cross AH, et al. Safety experience with extended exposure to ofatumumab in patients with relapsing multiple sclerosis from Phase 2 and 3 clinical trials. MSVirtual 2020, P0234.
- Hauser SL, et al. N Engl J Med. 2020;383:546–57.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Long-term safety and efficacy of ozanimod in RMS Next Article
Less thalamic atrophy in patients initiating ocrelizumab earlier »
« Long-term safety and efficacy of ozanimod in RMS Next Article
Less thalamic atrophy in patients initiating ocrelizumab earlier »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

November 25, 2020
Serum NfL as biomarker for suboptimal treatment response
August 27, 2019
Long-term effects of established treatments
July 30, 2019
McDonald Criteria MS often misapplied and misunderstood
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy